Issuer/Instrument | Industry/ Rating |
% to Net Assets |
---|---|---|
Equity & Equity Related |
||
Reliance Industries Ltd. | Petroleum Products | 13.28 |
HDFC Bank Ltd. | Banks | 9.65 |
ICICI Bank Ltd. | Banks | 8.73 |
Infosys Ltd. | IT - Software | 8.70 |
HDFC Ltd. | Finance | 6.62 |
Tata Consultancy Services Ltd. | IT - Software | 5.19 |
ITC Ltd. | Diversified FMCG | 4.07 |
Kotak Mahindra Bank Ltd. | Banks | 3.64 |
Hindustan Unilever Ltd. | Diversified FMCG | 3.61 |
Larsen And Toubro Ltd. | Construction | 3.35 |
State Bank Of India | Banks | 3.11 |
Axis Bank Ltd. | Banks | 3.04 |
Bajaj Finance Ltd. | Finance | 2.95 |
Bharti Airtel Ltd | Telecom - Services | 2.51 |
Asian Paints Ltd. | Consumer Durables | 2.30 |
Maruti Suzuki India Limited | Automobiles | 1.79 |
Mahindra & Mahindra Ltd. | Automobiles | 1.71 |
HCL Technologies Ltd. | IT - Software | 1.58 |
Sun Pharmaceuticals Industries Ltd. | Pharmaceuticals & Biotechnology | 1.56 |
Titan Company Ltd. | Consumer Durables | 1.51 |
Bajaj Finserv Ltd. | Finance | 1.39 |
Tata Steel Ltd. | Ferrous Metals | 1.31 |
Ultratech Cement Ltd. | Cement & Cement Products | 1.16 |
Power Grid Corporation Of India Ltd. | Power | 1.12 |
National Thermal Power Corporation Limited | Power | 1.11 |
Nestle India Ltd. | Food Products | 1.06 |
Tech Mahindra Ltd. | IT - Software | 1.00 |
IndusInd Bank Ltd. | Banks | 0.97 |
Wipro Ltd. | IT - Software | 0.96 |
Dr Reddys Laboratories Ltd. | Pharmaceuticals & Biotechnology | 0.76 |
Equity & Equity Related - Total | 99.74 | |
Net Current Assets/(Liabilities) | 0.26 | |
Grand Total | 100.00 |
Regular Plan
Fund Manager | Mr. Devender Singhal & Mr. Satish Dondapati* |
Benchmark | S&P BSE SENSEX TRI |
Allotment date | June 6, 2008 |
AAUM | Rs20.33 crs |
AUM | Rs21.38 crs |
Folio count | 1,543 |
Portfolio Turnover | 12.73% |
Tracking Error: | 0.04% |
Through Exchange: 1 Unit ,
Through AMC: 10000 Units,
Ideal Investment Horizon: 5 years and
above
Entry Load: Nil. (applicable for all plans)
Exit Load:
Nil (applicable for all plans)
Regular: 0.28%
Fund
Benchmark
* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.